Ubs Group Ag Belite Bio, Inc Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$29.5 - $46.02 $15,782 - $24,620	-535 Reduced 60.59%	348 $15,000
Q3 2023 Nov 09, 2023	BUY	$12.53 - $36.64 $7,304 - $21,361	583 Added 194.33%	883 $28,000
Q2 2023 Aug 11, 2023	BUY	$11.18 - $30.2 $2,012 - $5,436	180 Added 150.0%	300 $4,000
Q1 2023 May 12, 2023	SELL	$25.61 - $33.5 $104,924 - $137,249	-4,097 Reduced 97.15%	120 $3,000
Q4 2022 Feb 08, 2023	BUY	$25.08 - $33.32 $105,762 - $140,510	4,217 New	4,217 $127,000
Q2 2022 Aug 10, 2022	BUY	$8.87 - $34.28 $6,058 - $23,413	683 New	683 $21,000

187K

Ticker BLTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,867,400
Market Cap $1.16B
Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.